论文部分内容阅读
目的:探讨CK20和Cjun联检在膀胱癌诊断中的临床应用价值。方法:采用免疫组化SABC法检测150例膀胱癌组织中CK20和Cjun的表达水平,并与75例正常体检者膀胱组织中CK20和Cjun的表达水平进行比较。结果:CK20在膀胱癌组织中的阳性率为81.33%,在正常膀胱组织中的阳性率为0,两者比较有显著性差异(P<0.01),CK20在膀胱癌G1、G2和G3中的阳性率分别为69.84%、82.35%、100.00%,组间比较有显著性差异(P<0.01);Cjun在膀胱癌组织中的阳性率为91.33%,在正常膀胱组织中的阳性率为8.00%,两者比较有显著性差异(P<0.01),Cjun在膀胱癌G1、G2和G3中的阳性率分别为85.71%、92.16%、100.00%,组间比较无显著性差异(P<0.01)。结论:CK20和Cjun在膀胱癌组织中表达明显增高,采用病理分析和临床分析来提高对膀胱癌患者诊断中的准确性。
Objective: To investigate the clinical value of joint detection of CK20 and Cjun in the diagnosis of bladder cancer. Methods: The immunohistochemical SABC method was used to detect the expression of CK20 and Cjun in 150 cases of bladder cancer and the expression of CK20 and Cjun in bladder tissues of 75 normal controls were compared. Results: The positive rate of CK20 in bladder cancer tissues was 81.33%, while that in normal bladder tissues was 0 (P <0.01). The positive rate of CK20 in bladder cancer tissues of G1, G2 and G3 The positive rates were 69.84%, 82.35% and 100.00%, respectively. There was significant difference between the two groups (P <0.01). The positive rate of Cjun in bladder cancer was 91.33% and in normal bladder was 8.00% (P <0.01). The positive rates of Cjun in G1, G2 and G3 of bladder cancer were 85.71%, 92.16% and 100.00%, respectively. There was no significant difference between the two groups (P <0.01) . Conclusion: CK20 and Cjun expression in bladder cancer was significantly increased, the use of pathological analysis and clinical analysis to improve the diagnosis of bladder cancer patients in the accuracy.